Skip to content
Sep 09 2015

Small/Micro Cap Biotechnology: Still Richly Valued

  • Sep 9, 2015

Despite the group’s big losses since May, the results show Small/Micro Cap Biotechs are still richly valued. As market volatility heats up, this group faces additional downside risk.


For full access, please enter your credentials.
Remember Me

About The Author

Jun Zhu / Sr. Research Analyst & Co-Portfolio Manager